Clinical Trial Update: A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase II clinical trial evaluating ASC22, a subcutaneously injected PD-L1 antibody, in patients with chronic hepatitis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ASC22 (anti-PD-L1 monoclonal antibody)

Snippet

Sponsor: Ascletis Pharmaceuticals Co., Ltd. | Conditions: Chronic Hepatitis b | Phase 2 | Status: COMPLETED